Jupiter Neurosciences Files S-1/A Amendment

TL;DR

JUPITER NEUROSCIENCES (JUPITER) filed an S-1/A, looks like they're still prepping for a public offering.

AI Summary

Jupiter Neurosciences, Inc. filed a Pre-Effective Amendment No. 22 to its Form S-1 Registration Statement on October 18, 2024. This filing, under Registration No. 333-260183, updates information for the company, which is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. The company's principal executive offices are located in Jupiter, Florida.

Why It Matters

This S-1/A filing indicates Jupiter Neurosciences is continuing its process to register securities, potentially for an upcoming public offering or other significant corporate action.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with companies seeking to raise capital through public offerings, which inherently carry market and execution risks.

Key Numbers

• 22 — Pre-Effective Amendment Number (Indicates this is the 22nd update to the registration statement.)

Key Players & Entities

• JUPITER NEUROSCIENCES, INC. (company) — Registrant
• October 18, 2024 (date) — Filing Date
• 333-260183 (registration_number) — SEC Registration Number
• Delaware (jurisdiction) — State of Incorporation
• 2834 (sic_code) — Standard Industrial Classification Code
• Jupiter, Florida (location) — Principal Executive Offices Location
• Christer Rosén (person) — Chief Executive Officer

FAQ

Filing Documents

• forms-1a.htm (S-1/A) — 256KB
• ex23-1.htm (EX-23.1) — 4KB
• 0001493152-24-041537.txt ( ) — 261KB

From the Filing

filed with the U.S. Securities and Exchange Commission on October 18, 2024 Registration No. 333-260183 UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 22 TO Form S-1 REGISTRATION UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-4828381 (State or other jurisdiction of incorporation or organization) (Primary (I.R.S. Employer Identification Number) Jupiter Neurosciences, Inc. 1001 North US HWY 1, Suite 504 Jupiter, Florida 33477 Telephone: (561) 406-6154 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Christer Rosén Chief Executive Officer Jupiter Neurosciences, Inc. 1001 North US HWY 1, Suite 504 Jupiter, Florida 33477 Telephone: (561) 406-6154 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Laura Anthony, Esq. Craig D. Linder, Esq. Anthony, Linder & Cacomanolis, PLLC 1700 Palm Beach Lakes Blvd., Suite 820 West Palm Beach, Florida 33401 Telephone: (561) 514-0936 Facsimile: (561) 514-0832 Ralph De Martino, Esq. Cavas Pavri, Esq. ArentFox Schiff LLP 1717 K Street NW Washington, DC 20006 Telephone: (202) 857-6000 Facsimile: (202) 857-6395 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated reporting company Emerging growth company If an emerging growth company, indicate by check market if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a) may determine. EXPLANATORY NOTE This Amendment No. 22 is being filed solely for the purpose of filing Exhibit 23.1, the Consent of Assurance Dimensions, to this registration cover page and Part II of the Registration Statement. This Amendment No. 22 does not contain a copy of the prospectus included in the Registration Statement, which remains unchanged from Amendment No. 21 to the Registration Statement filed on September 13, 2024, and consists only of the cover page, this explanatory note and Part II of the Registration Statement. PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 13. Other Expenses of Issuance and Distribution The following table sets forth all expenses to be paid by us, other than estimated underwriting discounts and commissions, in connection with the offer and sale of common stock by us and the Selling Stockholders. All amounts shown are estimates except for the SEC registration fee, the Nasdaq Capital Market listing fee and the FINRA filing fee: Type Amount SEC Registration Fee $ 4,686 FINRA Filing Fee 5,263 Nasdaq Capital Market Listing Fee 50,000 Legal Fees and Expenses 200,000 Accounting Fees and Expenses 120,000 Accountable Fees 175,000 Non-Accountable Fees 110,000 Transfer

View Full Filing

View this S-1/A filing on SEC EDGAR